NCT05463224View on ClinicalTrials.gov

Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 2, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions

NSCLC

Interventions

DRUG

Lazertinib group

Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Myung-Ju Ahn

OTHER